Cambridge, MA - (NewMediaWire) - March 12, 2019 - IIOT-OXYS, Inc. (OTCPink: ITOX): IIOT-OXYS, Inc. announced today the first closing of a round of funding consisting of senior secured promissory notes in the aggregate amount of $100,000. The promissory notes have a conversion price of $0.20 and the warrants issued in connection with the promissory notes have an exercise price of $0.30. Details can be found in our 8-K filing. Cliff Emmons, CEO of IIOT-OXYS, Inc., stated, “I am pleased to announce the continued support with respect to our funding needs. This financing provides the company with the flexibility to implement new initiatives as related to sales and marketing and maintain the momentum with current customers. We continue to see unique opportunities for structural health monitoring and industrial applications within various markets, including but not limited to Biotech, Medtech and Pharma.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About UsIIOT-OXYS, Inc. uses a variety of sensors to capture and analyze massive amounts of data using Machine Learning and proprietary algorithms to identify discreet patterns and anomalies which can be associated to specific real-world events and used to provide actionable mission critical insights for the Medical/Pharmaceutical, Manufacturing, Agriculture, Defense, and Structural Health, and other industries. IIOT-OXYS, Inc. edge computing open-source hardware and proprietary ML algorithms employ our Minimally-Invasive Load Monitoring (MILM) technology to simply gather data and gain insights to monitor, scope, move from preventive to predictive maintenance, and even optimize development and manufacturing processes. For additional information visit www.oxyscorp.comForward-Looking StatementsThis news release contains forward-looking statements that reflect Management's current views about future events and financial performance. Forward-looking statements often contain words such as ''expects,'' ''anticipates,'' ''intends,'' or ''believes.'' Our forward-looking statements are subject to a number of risks and uncertainties that may cause actual results and events to differ materially from those projected in the forward-looking statements. Risks and uncertainties that could adversely affect us include, without limitation, the loss of major customers, our failure to obtain new contracts, our inability to patent products or processes, our infringement of patents held by others, our inability to finance our business and the other risks and uncertainties that are discussed in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this news release are made only as of the date of this news release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact: Andrew Barwicki Phone: 516-662-9461 Email: andrew@barwicki.com

Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech AwardAtlanta, GA - (NewMediaWire) - March 12, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today announced its selection as a finalist in two award categories at this year’s 12th Vaccine Industry Excellence (ViE) Awards program, held in conjunction with the 19th World Vaccine Congress. The Company’s unique immuno-oncology product (GeoVax MVA-VLP-MUC1) was selected as a finalist for the “Best Therapeutic Vaccine Award” and GeoVax’s novel MVA-VLP vaccine platform was selected as a finalist for the “Best New Vaccine Technology Award.” The ViE Awards will be announced on April 15.David Dodd, GeoVax President and CEO, commented, “We are humbled and honored to receive this high recognition of our ongoing efforts related to both our product development efforts and the recognized value of our unique platform technology and expertise. Last year, we were honored in receiving the 2018 “Best Biotech” ViE Award, and to be a finalist for the “Best Prophylactic Vaccine” for our Zika vaccine candidate. This year’s selection as a finalist in two categories is further humbling, recognizing the breadth of exciting new developments underway in vaccines and immunotherapies. As we continue to successfully advance GeoVax’s development programs on multiple fronts, we are focused on moving several development programs into clinical evaluation, addressing various infectious diseases and cancer indications. I want to thank our outstanding team and our many collaborators, all of whom vastly contributed to this accomplishment.”About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and various cancers using its MVA-VLP vaccine platform. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.Contact: GeoVax Labs, Inc. investor@geovax.com 678-384-7220 LinkedIn: www.linkedin.com/company/geovax-inc-/ Twitter: @Geovax_News

Lance Goudzwaard Appointed to Head Commercialization and Customer Relations for NuGenerex Distribution Solutions SubsidiaryMIRAMAR, FL - (NewMediaWire) - March 12, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to announce the appointment of Lance Goudzwaard as the Chief Commercial Officer for NuGenerex Distribution Solutions (NDS), the company’s wholly-owned subsidiary. Mr. Goudzwaard will be responsible for the delivery and operation of the management services organization (MSO) platform that is currently operational in five states, with an aggressive growth strategy designed to expand the model to 27 states in the next several months. Mr. Goudzwaard will also focus on building and developing our durable medical equipment (DME) service offering called DME-IQÔ, a software system being introduced to the orthopedic market with turnkey services to support the development and management of compliant and profitable in-office DME programs. The NDS DME-IQ program includes vendor negotiations to decrease cost of goods (COGs), oversight of coding during the billing process, management of the appeals process using patient focused support personnel to improve insurance collections, and technology enabled systems that ensure compliance with state and federal regulations.“We are extremely proud to have Lance, a highly regarded thought leader in the field of practice management, joining our team,” said Terry Thompson, COO of Generex and President of NuGenerex Distribution Solutions. “In his role, Lance will work with the NuGenerex family of companies to expand the company’s portfolio of ancillary health services while advancing the corporate mission to provide end-to-end solutions for physicians and patients, leading our client services team, MSO operations, and new product introductions. His vast experience and extensive network will truly enhance the strength of the NDS operation.”Mr. Goudzwaard has built a 25+ year career in healthcare as a senior executive implementing operational strategies that result in high impact sales, new business development, and organizational profitability. A nationally recognized speaker, author and thought leader in his field, Mr. Goudzwaard is one of less than a thousand fellows in the American College of Medical Practice Executives. As principle consultant for HealthConnectors, he has led multi-level project teams in the portfolio expansion of ancillary services. His expertise has been sought as an advisory board member for multiple mid-range healthcare organizations. On the national level, Mr. Goudzwaard has served as President and Chairman of the Western Region for the Medical Group Management Association (MGMA).Prior to joining NuGenerex, Mr. Goudzwaard served as an executive in a variety of healthcare settings including hospital, employed physician-based practices, and private practices. His breadth of operational and financial experience spans several roles including Chief Operating Officer (COO) of a large specialty orthopedic and spine conglomerate and Chief Executive Officer (CEO) of a gastroenterology practice that had 17 locations, 5 Ambulatory Surgery Centers along with an Anesthesia and Pathology practice, giving him an extensive background to lead the MSO operations for NuGenerex.Mr. Goudzwaard holds an undergraduate degree from the University of Wyoming and a Master of Science in Health Administration from the University of Colorado.“Growth and diversification are key to success within the healthcare landscape,” said Mr. Goudzwaard. “I welcome the opportunity to build NuGenerex into a new kind of healthcare company that enhances the physician patient experience with a range of ancillary healthcare services that offer new business opportunities for physician practices to improve outcomes through patient-centric care.”About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient-centric care from rapid diagnosis through delivery ...

Vancouver, BC - (NewMediaWire) - March 12, 2019 - iTokk, Inc. (OTC PINK: IKTO) (the "Company"), is pleased to announce that on Mar 7, 2019 the British Columbia Securities Commission (BCSC) issued the Company a “Partial Revocation Order” to permit the completion of a private placement.The Partial Revocation Order will allow the Company to complete a non-brokered placement of Common Shares or debt securities that are convertible into Common Shares for aggregate gross proceeds of up to US$250,000 (the Private Placement). The Company will rely on the exemption under section 2.3 of National Instrument 45-106 Prospectus Exemptions (NI 45-106). The intended use of proceeds for the Private Placement are for legal, accounting, and audit fees to bring the Company’s financials current and fully reporting.On October 9, 2010, the BCSC issued an order (the Cease Trade Order) under Section 164 of the Securities Act, R.S.B.C. 1996, c. 418 (the Act) that all trading in the securities of the Company cease until it files the required records referred to in the Cease Trade Order. The Company has applied to the BCSC under National Policy 12-202 Revocation of Certain Cease Trade Orders for an order under section 171 of the Act for a partial revocation of the Cease Trade Order to permit certain trades of its securities.The Company intends to file an application for a full revocation of the Cease Trade Order after it brings all continuous disclosure filings current. As the Private Placement would involve a trade of securities and acts in furtherance of a trade of securities, the Private Placement could not be completed without a partial revocation of the Cease Trade Order.The Partial Revocation Order also allows the Company to further its previously announced acquisition of Water Street Profile Services Inc (“The Profile”). Kevin Penstock, CEO of the Company, stated, “The partial revocation sets the stage for us to bring all continuous disclosure filings current and complete the acquisition of The Profile and the private placement” Mr. Penstock further commented, “We are grateful to our shareholders for being so patient and we look forward to growing the business at a more rapid rate.”Pursuant to the previously announced Letter of Intent, the Company and The Profile will enter into negotiations of certain definitive agreements whereby the Company will acquire 100% of the shares of The Profile for a purchase price of US$4,000,000.There is no guarantee that the Company will obtain the issuance of a full revocation order in the future from the BCSC.About Water Street Profile Services Inc. (The Profile)Founded in 2009, The Profile manages approximately 34,000 sf in some of Vancouver’s trendiest neighborhoods; Gastown, Downtown’s financial district, and Lower Lonsdale in North Vancouver. With over 400 Work spaces, 20 board rooms and meeting spaces, 1 amazing workspace club; The Profile takes awesome entrepreneurs and gives them the amazing space and resources that they need for success. More than just office space, our coworking environment is a unique lifestyle business community and workspace. For more information please visit www.theprofile.caAbout iTokk, Inc. (IKTO)Formerly involved in telecommunications, the Company is currently in the process of strategic repositioning and restructuring.IKTO is an OTC reporting issuer under Multilateral Instrument 51-105 - Issuers Quoted in the U.S. Over the-Counter Markets. IKTO’s Common Shares are currently traded on the “OTC Pink” marketplace under the symbol IKTO. IKTO’s securities are not traded on any market in any jurisdiction in Canada. However, On October 8, 2010, the Executive Director of the British Columbia Securities Commission (the BCSC) (the “Executive Director”) issued an order (the “Cease Trade Order”) under section 164(1) of the Securities Act, R.S.B.C. 1996, c. 418 (the “Act”) that all trading in the securities of IKTO cease until it files the required records referred to in the Cease Trade Order. IKTO was incorporated under the laws of Nevada on September 19, 2003, and was ...

Phoenix, AZ - (NewMediaWire) - March 12, 2019 - For The Earth Corporation (the “Company” or “FTEG”) (OTCMKTS: FTEG) issues the following Letter to Shareholders from the CEO:Dear Valued Shareholder,As our recent communications have outlined, we are transitioning into a vertically integrated CBD producer and retailer. We are extremely grateful to our committed shareholders for joining us on this exciting journey. Today, I wanted to bring you up to date on what we have accomplished and what our next steps will be.First off, our new website is up and live. You can find it at ftegco.com. Be sure to check back often to follow our progress there.Next, I am very excited to announce that we are making strong progress on acquiring our new state-of-the-art CBD extraction and production facility. We have sharply narrowed down our list of top candidates with the goal of closing on a facility by next month. This is an enormously important piece of the puzzle for setting our fully integrated vision in motion. We will be outfitting the facility with a high-capacity supercritical CO2 extraction machine along with other essential equipment and moving quickly into production.I am also very excited to report that we will be launching our own distribution facility in Phoenix, AZ. That facility should be fully up and running by April 2 – and possibly sooner than that. This will be our distribution hub and will serve as a primary sourcing point for all of our major end markets, including full-spectrum high-potency CBD products, a range of pet products, and our Bacteria Elimination cleaning products.With our new emphasis on the rapidly growing CBD market, it’s easy to forget that we have tremendous traction in the hi-tech cleaning products marketplace. Our Clean Life brand uses advanced Nano-mechanics to destroy pathogens and leave a protective shield (our “Advanced Coating Technology”) on surfaces to inhibit the growth of new pathogens where treatment with Clean Life products has occurred – all without the use of harsh or harmful chemicals.If you want to understand more about our cleaning products, our technology, or the science behind this process, please visit our Clean Life products site at cleanlifecorp.com.Finally, I wanted to update our recent moves to expand our CBD retail footprint. We will be interfacing with end-market consumers in a range of ways, as we have noted in recent communications. Two of the most powerful avenues are our CBD mall kiosks and CBD vending machines.Our mall kiosk strategy will focus on both human CBD products and pet products, including CBD for pets, which is a surprisingly powerful growth market. It shouldn’t be surprising if you take a moment to think about it. CBD is an extremely effective agent on so many fronts for animal physiology given its interaction with the endocannabinoid system. Those same CB1 and CB2 receptors that have such an impact on our own physiology are present in our furry friends as well. And most pet owners desire natural, organic products that increase the well-being of their pets.To give you a sense of how big this market could become, pet owners spent over $30B in 2016 on pet supplies, treatments, and veterinary care, according to the American Pet Products Association. Some percentage of that spending is a substitution target for CBD products.Our first kiosk will focus on human CBD products. Our second will focus on the pet market.In addition, our Las Vegas retail footprint will be open and active beginning next week. We also plan to expand aggressively into the Arizona and Florida markets next.Best Regards,Nelson Grist, CEOAbout For The Earth CorporationFor The Earth Corporation is an emerging integrated CBD producer and retailer in the United States. The Company is in the process of establishing a vertical framework that will extend from cultivation to extraction and production to a strategic retail footprint that includes multiple locations in Las Vegas and New York featuring mall kiosks, vending machines, e-commerce, and full store locations serving both the human and pet CBD ...

Seattle, WA - (NewMediaWire) - March 12, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF). The company recently announced a new proof-of-concept for its advanced cannabis biomarker technology, which enables cultivators, dispensaries, and regulators to easily trace products across the supply chain.The cannabis industry is projected to exceed $146 billion by 2025, according to Grand View Research, driven by the legalization of adult-use and medical cannabis around the world. With the breakneck pace, the industry has faced a number of growing pains along the way. Product recalls, counterfeit products, mislabeled products, and supply chain issues have introduced challenges for growers, dispensaries, consumers, and regulators.Supply Chain ChallengesThe cannabis industry has experienced rapid growth over the past several years, but there have been plenty of growing pains along the way. According to one study, 35 percent of more than 80 cultivars tested had genetics that didn’t match the cultivar being sold. Consumers were buying Sativa cultivars that were advertised as Indica and vice versa. California cannabis labs are also finding toxic metals in vape cartridges, which could cause serious health issues.Counterfeit products have caused other problems. G Pen, a leading high-end portable vaporizer, was awarded $47 million in 2017 after suing more than 60 online retailers selling counterfeit versions of their products. Even worse, some dispensaries were found to be selling fake vape cartridges, which could introduce health risks since the contents of those cartridges are completely unknown and unregulated.“Legal cannabis markets around the world continue to express concern about black market production entering regulated systems,” says FluroTech CEO Danny Dalla-Longa. “Regulators, responsible for consumer protection, have noted an increase in the number of these allegations. Legal growers need to protect their brands and reputation, which we believe creates an expanding market for our technology.”Governments have also struggled to control the supply chain. Without a good way to track legal product, there’s no way for them to ensure that legal cannabis remains out of the black market and black market cannabis remains out of the legal market. Tracking solutions could also enable them to trace cannabis back to its origins for tax collection purposes, as well as to assist with any product recalls that may be issued.Please Click Here to Receive a FluroTech Investor Presentation and Future Updates.Biomarker-based SolutionsDNA biomarkers, short for biological markers, have become a popular way to track everything from clothing to livestock. After applying a spray solution, the DNA acts as a molecule-sized encrypted barcode that can be used to track almost anything across a supply chain. The fashion industry, for example, has used the technology to verify the authenticity of high-end clothing and accessories to combat counterfeit products.The same technology can be applied to the cannabis industry. By bonding to the plant, biomarker technologies can withstand processing and even show up in refined products, such as oils and edibles. Dispensaries, regulators, cultivators and other interested parties can feed the product into a reader to access the unique “encrypted barcode”. This information can be used to confirm the origin, strain, permit or other relevant information.While most conventional biomarking technologies utilize sprays, FluroTech’s CTO Dr. Elmar Prenner doesn’t believe that these will be acceptable under future Health Canada regulations. The company recently announced a proof-of-concept technique that introduces water-based biomarkers through the root system of cannabis and hemp plants, so that the nanoparticles are absorbed throughout all of the plant.Using the company’s cost-effective CompleTest™ equipped with biomarking scopes, these unique ...

Coconut Creek, FL - (NewMediaWire) - March 12, 2019 - NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) announces it has signed an agreement with Orlando Pharmacy, a USP 797 compliant compounding pharmacy, to provide its technologies and an innovative delivery system for pharmaceutical products.Craig Sicinski, a pharmacist and owner of Orlando Pharmacy and a board advisor to BioHealth Technologies, a CBD and nutraceutical AI PAAS (Platform As A Service) company, commented, “We are thrilled to have this new agreement with NutraLife and to use its technologies and delivery system in our pharmaceutical products. Our shared goal is to discover new innovations within the life sciences space.”Edgar Ward, CEO and Founder of NutraLife Biosciences, stated, “This is a great opportunity for us to expand our technologies and delivery systems into the Pharmaceutical marketplace. Pharmacist Craig Sicinski of Orlando Pharmacy is in-line with our mission to develop the most effective and efficient delivery systems. With Orlando Pharmacy, we are taking our first steps into the pharmaceutical marketplace.”“We are excited to explore the possibilities for our technologies and processes in the life sciences space and to have our technologies and delivery systems used in the creation of compounded pharmaceutical products by the pharmacists at Orlando Pharmacy, an experienced cGMP facility. We look forward to a long and rewarding relationship with Mr. Sicinski and his team at Orlando Pharmacy,” said Mr. Ward.Orlando Pharmacy is a USP 797 compliant pharmacy that has been serving the Orlando community for more than 60 years. Orlando Pharmacy is designated as a Good Neighbor Pharmacy, a network of more than 4,5000 independent pharmacies. Orlando Pharmacy prides themselves on their reputation for credibility, integrity, and always going the extra mile to meet the needs of its customers and patients.”NutraLife Biosciences, Inc. operates a multifaceted life sciences company. Since 2013, NutraLife's manufacturing facility has been registered with the FDA and operated in accordance with the GMP standard. The Company manufactures and distributes private label and branded nutraceutical and wellness products. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., the Company provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing. In February of 2019, the Company's subsidiary, NutraDerma Technologies, Inc. acquired its first product, a patented all natural dermal patch designed to ward off insects including mosquitoes.NutraLife Sciences is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). NLBS recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NLBS’s filings with the SEC can be viewed at www.sec.gov. NLBS’s CBD products and information about the company’s direct sales program can be found online at https://nutrahempcbd.com and by following the company on Instagram.* These statements have not been evaluated by the Food and Drug Administration.* This product is not intended to diagnose, treat, cure or prevent any disease.Forward-Looking StatementsThis communication from NutraLife BioSciences, Inc. (the “Company”) contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and ...